FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies

[1]  C. Pashos,et al.  The health economics of bladder cancer , 2012, PharmacoEconomics.

[2]  Hester F. Lingsma,et al.  Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer , 2010, Clinical Cancer Research.

[3]  Dieter Jocham,et al.  Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. , 2010, European urology.

[4]  Y. Kanai,et al.  Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non‐muscle invasive bladder cancer , 2010, Cancer science.

[5]  Ewout W Steyerberg,et al.  Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. , 2009, The Journal of urology.

[6]  E. Steyerberg,et al.  Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? , 2009, BJU international.

[7]  T. H. van der Kwast,et al.  The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour , 2009, The Journal of pathology.

[8]  F. Hamdy,et al.  FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. , 2009, European urology.

[9]  E. Steyerberg,et al.  Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison , 2008, BJU international.

[10]  E. Zwarthoff.  Detection of tumours of the urinary tract in voided urine , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[11]  J Alfred Witjes,et al.  The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer , 2007, Nature Clinical Practice Urology.

[12]  F. Hamdy,et al.  [Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract]. , 2006, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[13]  N. Malats,et al.  Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[15]  K. Rieger-Christ,et al.  Rieger‐Christ KM, Mourtzinos A, Lee PJ, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. (2003) 98(4):737–44. , 2003 .

[16]  K. Rieger-Christ,et al.  Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection , 2003, Cancer.

[17]  T. H. van der Kwast,et al.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Roehrborn,et al.  Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. , 2002, The Journal of urology.

[19]  Y Z Almallah,et al.  Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. , 2000, Urology.

[20]  M. Wright,et al.  Surveillance for bladder cancer: the management of 4.8 million people , 2000, BJU international.

[21]  D. Redelmeier,et al.  Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. , 2000, The Journal of urology.

[22]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[23]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[24]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.